LeukoScan European Union - English - EMA (European Medicines Agency)

leukoscan

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - diagnostic agents - this medicinal product is for diagnostic use only.leukoscan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.leukoscan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.

EVOGAM normal immunoglobulin (human) 16% w/v, 3.2g/20mL injection solution vial for subcutaneous use Australia - English - Department of Health (Therapeutic Goods Administration)

evogam normal immunoglobulin (human) 16% w/v, 3.2g/20ml injection solution vial for subcutaneous use

csl behring australia pty ltd - normal immunoglobulin, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

EVOGAM normal immunoglobulin (human) 16% w/v, 1.6g/10mL injection solution vial for subcutaneous use Australia - English - Department of Health (Therapeutic Goods Administration)

evogam normal immunoglobulin (human) 16% w/v, 1.6g/10ml injection solution vial for subcutaneous use

csl behring australia pty ltd - normal immunoglobulin, quantity: 1.6 g - injection, solution - excipient ingredients: water for injections; human immunoglobulin a; glycine - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

EVOGAM normal immunoglobulin (human) 16% w/v, 0.8g/5mL injection solution vial for subcutaneous use Australia - English - Department of Health (Therapeutic Goods Administration)

evogam normal immunoglobulin (human) 16% w/v, 0.8g/5ml injection solution vial for subcutaneous use

csl behring australia pty ltd - normal immunoglobulin, quantity: 0.8 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

VOGLIBOSE OD Tablets 0.2mg "KYORIN" (ボグリボースOD錠0.2mg「杏林」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose od tablets 0.2mg "kyorin" (ボグリボースod錠0.2mg「杏林」)

kyorin rimedio co.,ltd. - voglibose - yellowish white tablets, diameter: 6.5 mm, thickness: 2.4 mm

VOGLIBOSE OD Tablets 0.2mg "SAWAI" (ボグリボースOD錠0.2mg「サワイ」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose od tablets 0.2mg "sawai" (ボグリボースod錠0.2mg「サワイ」)

sawai pharmaceutical co.,ltd. - voglibose - yellowish white tablet, diameter: 7.5 mm, thickness: 3.8 mm

VOGLIBOSE OD Tablets 0.3mg "KYORIN" (ボグリボースOD錠0.3mg「杏林」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose od tablets 0.3mg "kyorin" (ボグリボースod錠0.3mg「杏林」)

kyorin rimedio co.,ltd. - voglibose - slightly yellow tablets, diameter: 7.0 mm, thickness: 2.5 mm

VOGLIBOSE OD Tablets 0.3mg "SAWAI" (ボグリボースOD錠0.3mg「サワイ」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose od tablets 0.3mg "sawai" (ボグリボースod錠0.3mg「サワイ」)

sawai pharmaceutical co.,ltd. - voglibose - faint yellow tablet, diameter: 8.5 mm, thickness: 4.4 mm

VOGLIBOSE TABLETS 0.2mg "NP" (ボグリボース錠0.2mg「NP」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose tablets 0.2mg "np" (ボグリボース錠0.2mg「np」)

nipro corporation - voglibose - white tablet with split line, diameter: 7.0 mm, thickness: 2.7 mm

VOGLIBOSE TABLETS 0.2mg "YD" (ボグリボース錠0.2mg「YD」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

voglibose tablets 0.2mg "yd" (ボグリボース錠0.2mg「yd」)

daiichi sankyo espha co., ltd. - voglibose - white tablet, diameter 7 mm, thick 2.7 mm